LOF variants in regulators of complement, such as CD46, CFH (factor H), and CFI (factor I), can result in hyperactivation of the complement pathway with increased consumption of C3, and patients frequently present with atypical hemolytic uremic syndrome (aHUS) (124, 125). Here, C3 is linked to atypical hemolytic-uremic syndrome.